In cancer cells expressing HMGA2, we propose that the protein mitigates the effects of both TOP2 targeting drugs by a combination of DNA supercoil constrainment and TOP2A catalytic activation, hence acting as a DNA supercoil ‘sink’ (Fig. 8B). This evidence concerns the gene HMGA2 and cancer.